Search
for
Sort by
Research 61–90 of 777
- Treatment of Steroid-Resistant Beard-Restricted Alopecia Areata with Baricitinib
- Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo
- Alopecia Areata
- Ruxolitinib: A novel molecule in the management of dermatological disorders
- Continued treatment with baricitinib results in meaningful scalp responses among scalp non‐responder patients with eyebrow/eyelash regrowth in the first year
- JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience
- A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
- JAK1 Signaling Is Involved in the Induction of Mechanical Alloknesis in Atopic Dermatitis
- Successful treatment of concomitant alopecia universalis and Crohn’s disease with upadacitinib: A case report
- Ivarmacitinib in atopic dermatitis presenting with prurigo nodularis-like lesions and alopecia areata: a case report
- Successful Treatment of Extensive Ritlecitinib-Refractory Alopecia Areata with Upadacitinib
- S3886 Concurrent Management of Crohn's Ileitis and Alopecia Universalis With Upadacitinib
- Upadacitinib for the treatment of alopecia areata – A case report
- 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
- 41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial
- Peripheral neuropathy associated with tofacitinib use in alopecia universalis
- Management of comorbid Crohn's disease and alopecia universalis with upadacitinib and oral minoxidil.
- 170 Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index
- 69 Risk-benefit appraisal of systemic JAK inhibitors for alopecia areata: a comprehensive meta-analysis assessing safety and adverse effects
- JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
- Under Development JAK Inhibitors for Dermatologic Diseases
- Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
- A phase 2a trial of brepocitinib for cicatricial alopecia
- Alopecia areata
- Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2
- Successful Treatment of Extensive Ritlecitinib-Refractory Alopecia Areata with Upadacitinib
- An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: A case report and a review of the literature
- Recent Insight on the Management of Lupus Erythematosus Alopecia
- Pharmacological Treatment of Alopecia